Parkinson’s disease market projected to reach $7.2 billion by 2033

The Parkinson’s disease (PD) market across seven major markets is projected to grow from $3.3 billion in 2023 to $7.2 billion by 2033, representing a compound annual growth rate of 7.9%. This expansion is expected to be driven by an aging population and the introduction of disease-modifying therapies, symptomatic treatments, and reformulations.

Recent regulatory milestones include the FDA approval of AbbVie’s Juvmo (tavapadon), the first selective D1/D5 dopamine agonist, and the US launch of Supernus’s Onapgo. In Europe, NeuroDerm’s Onerji and Amneal’s Crexont/Hopledo have received EMA approval. While new therapies and emerging cell research offer growth opportunities, the market faces challenges from the loss of exclusivity for several branded products, which may allow cheaper generics to enter the market.